2010年1月22日～24日に米国オーランドにて開催された2010年 消化器癌シンポジウム(2010 Gastrointestinal Cancers
Symposium)より、大腸癌と胃癌の注目演題のレポートをお届けします。
演題レポートの冒頭には“Expert's view”として、臨床研究の第一線で活躍する監修ドクターのコメントを掲載しています。
2010年2月17日 演題レポート #402を更新しました。
2010年2月5日 サイトをアップしました。
 |
|
Randomized Phase 3 Study of Panitumumab with FOLFIRI vs FOLFIRI Alone as 2nd-line treatment in Patients with Metastatic Colorectal Cancer (mCRC): Patient Reported Outcomes (PRO).
Marc Peeters, et al. |
|
|
Efficacy findings from a randomized phase III trial of capecitabine plus
oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968):
No impact of age on disease-free survival (DFS).
Daniel G. Haller, et al. |
|
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC):
The influence of KRAS and BRAF biomarkers on outcome:
Updated data from the CRYSTAL trial.
Eric Van Cutsem, et al.
Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): A meta-analysis of the CRYSTAL and OPUS studies according to
KRAS and BRAF mutation status.
Claus-Henning Köhne, et al.
|
|
|
Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared
to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal
cancer (mCRC): PRIME trial.
Salvatore Siena, et al. |
|
|
Validation study of sentinel node mapping in gastric cancer:
Prospective multicenter trial in Japan.
Yuko Kitagawa, et al. |
|
 |
|
Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab:
The effect of infusional 5-FU or capecitabine on the outcomes of the MRC COIN trial in advanced colorectal cancer (ACRC).
Timothy S. Maughan, et al. |
|
|
5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: Long-term follow-up of NSABP C-07 with survival analysis.
Greg A. Yothers, et al. |
|
|
Safety of Panitumumab (pmab) in Combination With Chemotherapy From 5 Clinical Trials in 823 Patients With Metastatic Colorectal Cancer and Wild-Type (WT) KRAS Tumors.
Jean-Yves Douillard, et al. |
|
|
Epidermal-growth Factor Receptor (EGFR) Inhibitor-related skin Toxicity: Review of Primary Analysis Data from a PhaseⅡStudy (20060314) of Panitumumab with
FOLFIRI in the First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Meinolf Karthaus, et al. |
|
|
Primary analysis of a phase II study (20060314) combining first-line panitumumab (pmab) with FOLFIRI in the treatment of patients (pts) with metastatic colorectal cancer (mCRC).
Claus-Henning Köhne, et al. |
|
|
Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III
gastric cancer patients after curative D2 gastrectomy (OGSG 0604).
Yutaka Kimura, et al.
Feasibility study of adjuvant therapy with S-1 plus CDDP in gastric cancer.
Daisuke Takahari, et al. |
|
 |
 |
